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A cDNA encoding human endothelin 3 (ET-3) precursor was cloned from a cDNA library from the placenta, and its nucleotide and deduced amino 
acid sequences were determined. This ET-3 cDNA was found to contain 2.3 Lb pairs and encode prepro-ET-3 protein consisting of 224 amino 
acid residues. The putative big-ET-3 seems to consist of 42 amino acid residues. Two of the intron insertion sites were determined with information 
from nucleotide sequences of the cloned genomic ET-3 gene. This is the first direct evidence that the ET-3 gene is transcribed and expressed in 
the placenta. 
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1, INTRODUCTION 
A novel vasoconstrictor peptide, endothelin, was 
purified from the culture medium of porcine aortic en- 
dothelial cells and its cDNA was cloned [l]. We have 
already cloned human cDNA encoding prepro- 
endothelin from the cDNA library of the placenta and 
identified the 21 amino acid sequences of human and 
porcine endothelin [2]. Genomic DNA studies on en- 
dothelin have revealed that there is an endothelin gene 
family comprising 3 types of endothelin, i.e. endothelin 
1, 2 and 3 (ET-l, -2 and -3) [3]. ET-l, the first to be 
found, exists in many organs, such as the lung, kidney 
and brain, and has various biological functions in- 
cluding vasoconstriction [4]. As for ET-2 and ET-3, the 
functions except for vasoconstriction have not been ful- 
ly examined and the structures of their precursors, 
which are needed to understand the process of biosyn- 
thesis have not been elucidated. The presence of ET-2 
and ET-3 in vivo was not proven until precise tissue 
distribution studies of ETs could be done with the com- 
bination of a highly sensitive enzyme immunoassay 
@IA) of ETs and reverse phase high perform~ce li- 
quid chromatography (RP-HPLC) [S]. 
confirmed with ET-l-specific EIA. We tried to find 
direct evidence for ET-3 gene expression by cloning the 
cDNA encoding the precursor of ET-3 from the cDNA 
library of human placenta and succeeded in elucidating 
its structure. Based on structural comparison between 
the precursor of ET-1 and ET-3, the common process- 
ing steps of ETs from the precursors could be ex- 
plained. 
Here we present he first report on the nucleotide and 
the predicted amino acid sequences of human 
prepro-ET-3 ,’ 
2. MATERIALS AND METHODS 
2.1, Materials 
Restriction enzymes, T4 DNA ligase and XhoI linker, were obtain- 
ed from New England Biolabs (Beverly, MA, USA) and Nippon Gene 
(Tokyo, Japan). Exonuclease III and VII were from Takara Shuzo 
(Kyoto, Japan) and Bethesda Research Labs. [cu-32P]dCTP was ob- 
tained from Amersham Co. DNA modification, ligation, and 
transformation were carried out as described by Maniatis et al. [6]. 
Particularly interesting is the distribution in rats of 
immunoreactive ET-3, which is abundant in the brain 
and intestine, and seems to be a brain-gut peptide [5]. 
The precise functions of this peptide remain unknown. 
2.2. Enzyme immunoassay of endothelins and RP-HPLC 
Preparation of the tissue extracts of the rat placenta (1.9 g wet 
weight) and their partial charaete~zation with RP-HPLC (TSR 
ODS-80 column, 4.6 x 250 mm, Tosoh, Japan) were conducted as 
described elsewhere f5]. Rat placentas were obtained from is-day 
pregnant Sprague-Dawley (SD) rats after bleeding under anesthesia. 
Enzyme immunoassay for ET-l(ET-2) and ET-3 was done under the 
protocol described elsewhere [7]. 
In the present study, we found that ET-3 also exists 
in the placenta, like ET-l, the presence of which was 
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2.3. Cloning and sequencing analysis of endothelin 3 cDNA 
A human placenta cDNA library constructed in Xgt 11 was obtained 
from Clontech Laboratories Inc. The cDNA library containing about 
1.8 x lo6 clones was screened with “P-labeled 650 bp genomic ET-3 
DNA fragment previously cloned (unpublished resutts) and synthetic 
33mer oligonucleotides corresponding to the 11 amino acids Iocated 
upstream of the N-terminal amino acid (Cys) of ET-3 predicted from 
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the cloned genomic ET-3 DNA [3]. Plaque hybridization was con- 
ducted at 58°C for 16 h and washed with 2 x SSC (saline sodium 
citrate solution; 1 x SSC = sodium chloride, 8.765 g/l, sodium 
citrate, 4.41 g/l) buffer at 56°C [S]. The cloned cDNA from the 
hybridization positive phage was subcloned into the plasmid 
pUC 118/l 19. Then various clones containing the 3 ’ - or 5 ‘-deleted 
plasmid were used to prepare single stranded DNAs for DNA sequen- 
cing by the dideoxynucleotide chain termination method with 
[cy-32P]dCTP [9,10]. The nucleotide sequences were also determined 
with an automatic DNA sequencer, ABI Model 370 A (Applied 
Biosystems Inc.) as described previously [ 111. 
2.4. Chsttwtiort of expression plasmid and cell transformation 
Plasmid pHET-3(P) was digested with restriction enzyme, EcoRI, 
and a 2.3 kb cDNA fragment was obtained. After filling the single- 
stranded portion with the T4 DNA polymerase reaction, the XhoI 
linker, 5’-pd(CCTCGAGG)-3 ’ was ligated and the X/z01 fragment 
containing the whole coding region of ET-3 precursor was inserted in- 
to the XhoI site of pSVL 1121 to obtain plasmid pTS 6009. DNA 
transfection to COS-7 cells was performed as described previously 
1131. 
3, RESULTS AND DISCUSSION 
3 .l. Detection of immunoreactive ET-3 in the rat 
piacen ta 
The extracts were assayed with ET-l- (ET-2-) and 
ET-3-specific enzyme immunoassays as described 
previously. 
The sensitivity of EIA for ET-l (ET-2) and ET-3 is 
0.2 pg/well, which is enough to detect ET-1 (ET-2) or 
ET-3 in the blood or for the preparation of tissue ex- 
tracts. The crossreactivity of the ET-3 EIA was less 
than 0.1% with other ETs [ 14,151. The RP-HPLC pro- 
files of immunoreactive ET-l, ET-2 and ET-3 are 
shown in fig.1, with arrows indicating the fractions 
where the chemically synthesized ET-l, ET-2 and ET-3 
were eluted. The results showed that the immunoreative 
ET-3 was clearly separated from ET-l. ET-2, and the 
content of ET-3 in the rat placenta was estimated as 
one-tenth that of ET-l. ET-2 was present in only a 
small amount. In the case of human placenta, the con- 
tent of ET-3 was estimated as 4.2 + 1.2 pg/g wet tissue 
(n = 6) and about 20-fold ET-1 was detected (un- 
published results). As we could clone the ET-l cDNA 
from a cDNA library of human placenta, the existence 
of ET-l in the placenta was confirmed here by EIA. 
Precise studies on the tissue distribution of ETs, 
especially ET-3 have been reported elsewhere [5]. 
Our observations motivated us to clone the human 
ET-3 cDNA encoding the whole precursor from a 
cDNA library derived from human placenta and to try 
to explain how the processing steps of ET-3 might oc- 
cur from the big-ET-3 form, if exists in the precursor 
protein. 
3.2. Cloning and sequencing of ET-3 cDNA 
In the first hybridization screening test with the 32P- 
labeled 650 bp probe, 26 positive clones were obtained. 
As this probe had consensus sequences encoding 14 
amino acid residues, Asp*-Trp2’, of endothelins, in the 
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Fig.1. RP-HPLC profiles of the extract of the rat placenta. Each 
fraction was concentrated by lyophilization and subjected to EIA 
specific for ET-3 (solid bar) and ET-l and for ET-2 (open bar). The 
star marked position is the Met-sulfoxide form of ET-l. 
second and third screening 32P-labeled ET-3-specific 
33-mer oligonucleotide was used. Finally, one positive 
clone named AHET-3(P) (human endothelin 3 cDNA 
derived from the placenta) was obtained. The purified 
phage DNA of hHET-3(P) was treated with EcoRI and 
the cDNA insert was subcloned into a plasmid pUC 118 
named pHET-3(P). The partial restriction enzyme map 
and the sequencing strategy are shown in fig.2. The 
total sequenced nucleotides of pHET-3(P) cDNA were 
2299 bp, which encode the prepro-ET-3 protein con- 
sisting of 224 amino acid residues (fig.3). The 
molecular mass of the prepro-ET-3 was calculated as 
23946 Da. The amino acid sequence of the mature 
ET-3, Cys9’-Trpll’, is boxed in the figure. Like the 
big-ET-l, which is known to exist as an intermediate 
form in the post-translational processing of prepro- 
ET-l [ 15,161, a similar big form, big-ET-3 was found 
in prepro-ET-3. Big-ET-3 was found to consist of 42 
amino acid residues (Cy~~‘-Gly’~*) and cleaving pro- 
bably occurs at the dibasic amino acid pairs 
Arg95-Arg96 and Lys’39-Arg’40. The N-terminal 16 
amino acids of prepro-ET-3 may be the signal se- 
quence, which can be predicted by the method of von 
Heijne [16]. In the nucleotide sequences encoding this 
prepro-ET-3, there are 24 bp direct repeats correspon- 
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Fig.2. Restriction enzyme map and sequencing strategy for the cDNA 
insert in the plasmid pHET-3(P). The coding nucleotide sequences 
for prepro-ET-3 and mature ET-3 are indicated by open and closed 
boxes. The arrows indicate the direction of sequencing and location 
and the length of the sequenced regions. Representative restriction 
enzyme sites: A, AccI; B, BarnHI; Bg. Bg/II; H, NindIII; S, SphI; 
and E. linker EcoRI. 
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ding to 8 amino acid residues of Glu48-Thr-Val-Ala- The splicing acceptor site, the 5 ‘-end of the exon 
Gly-Pro-Gly-GluS5 and Gl~‘~-Glu~~. These sequences containing mature ET-3, was revealed to be GA, the 
were also found in the cloned genomic ET-3 DNA. nucleotide and the amino acid number is 162-163, the 
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CCAACCCCCACAGCTGGAGGGCGAGGCCAGCTGTACCCGGCCCCAGTGCCCTTTCGCGGCCACAAGCGGCCGTCCTCCT 
GGTCCGGTGCTCCGGCGCCTGATCTAGGTTC ATG GAG CC0 GGG CTG TGG CTC CTT TTC GGG CTC ACA 
_) 
Met Glu Pro Gly Leu Trp Leu Leu Phe Gly Leu Thr 
GTG ACC TCC CCC GCA :GA TTC GTG CCT TGC TCC CAG TCT GGG GAT GCT GGC AGO CCC CCC 
Val Thr Ser Ala Ala Gly Phe Val Pro Cys Ser Gln Ser Gly Asp Ala Gly Arg Arg Gly 
GTG TCC CAG GCC CCC ACT GCA CCC AGA TCT GAG GGG GAC TGT GAA GAG ACT GTG GCT GGC 
Val Ser Gln Ala Pro Thr Ala Ala Arg Ser Glu Gly ASP CYS Glu Glu Thr Val Ala Gly 
CCT GGC GAG GAG ACT GTG GCT GGC CCT GGC GAG GGG ACT GTG GCC CC0 ACA GCA CTG CAG 
Pro Gly Glu Glu Thr Val Ala Gly Pro Gly Glu Gly Thr Val Ala Pro Thr Ala Leu Gln 
GGT CCA AGC CCT GGA AGC CCT GGG CAG GAG CAG GCG GCC GAG GGG CCC CCT GAG CAC CAC 
Gly Pro Ser Pro Gly Ser Pro Gly Gln Glu Gln Ala Ala Glu Gly Ala Pro Glu His His 
CGA TCC AGO CCC TGC ACG TGC TTC ACC TAC AAG GAC AAG GAG TGT GTC TAC TAT TGC CAC 
Arg Ser Arg Arg Cys Thr Cys Phe Thr Tyr LYS Asp Lya Glu Cye Val Tyr Tyr Cys His 
CTG GAC ATC ATT TGG ATC AAC ACT CCC GA!A CAG ACG GTG CCC TAT GGA CTG TCC AAC TAC 
Leu Asp Ile Ile Trp Ile Asn Thr Pro Glu Gln Thr Val Pro Tyr Gly Leu Ser Asn Tyr 
AGA GGA AGC TTC COG GGC AAG AGO TCT GCG GGG CCA CTT CCA GGG AAT CTG CAG CTC TCA 
Arg Gly Ser Phe Arg Gly Lys Arg Ser Ala Gly Pro Leu Pro Gly Asn Leu Gln Leu Ser 
CAT COG CCA CAC TTG CGC TGC GCT TGT GTG GGG AGA TAT GAC AAG GCC TGC CTG CAC TTT 
HIS Arg Pro Hls Leu Arg Cys Ala Cys Val Gly Arg Tyr Asp Lys Ala Cys Leu Hls Phe 
TGC ACC CAA ACT CTG GAC GTC AGC AGA CAG GTT GAA GTC AAG GAC CAA CAA AGC AAG CAG 
Cys Thr Gln Thr Leu Asp Val Ser Arg Gln Val Glu Val Lys Asp Gln Gln Ser Lys Gln 
GCT TTA GAC CTC CAC CAT CCA AAG CTC ATG CCC CCC AGT GGA CTC GCC CTC GCT CCA TCT 
Ala Leu Asp Leu His His Pro Lys Leu Met Pro Gly Ser Gly Leu Ala Leu Ala Pro Ser 
ACC TGC CCC CGC TGC CTC TTT CAG GAA GGA GCC CCT TAG GAGGACAGGCCTGCAGCATCCTGGTCTC 
Thr Cys Pro Arg Cys Leu Phe Gln Glu Gly Ala Pro ++* 
GGGAGGCTTCTGTCATTGCTCACACACAGTTCAGATTTCCACCTCTTTATAGACAAGAAGTGAATTTGCCTGGGGCAGAA 
CACCCACCCAAAGAGTCCCCACTTAACAATACCCCCCCCCCACGGCAAGAATGCCCAAATCCGAATGACCCCAGTTTTCC 
TAATGAGTAAAATGATCCCAGATGTGCCCCAGAGCATGACGCCTGCAGCTCCGGTTTCATGCAGGAAATTGGTTTTGGAG 
AGTTTTGGCAAGTTGGAAAGCCACTTACTGGCTTTTGACATGACTTCTCTTGGAGAATAAGTGGACTCCAAGCTAACTCT 
TTGCAAATGTAAACACATGTCCATCTTGTAATAAATGCAAAATGCCCGTGCAGCAGAAGCATGCGACTTTCATATCCTTG 
CCTAGAATAGGCTGCATGGTGTATGTCAGTGAGGGCCACGAGGCGTCGGCTTTAGACACAGATCATAGCTCTACAGGAGT 
TTATGAATTTGAAGCTTATGGGATTTTGGCAGAGAAATTTTCAGCTGTGCTTGATACCCACCAAAAGAATGTATCTCGAA 
AGAATGAAGGAAGAAGAAAAAAGGATCCTTGATGTTTGTGACAAGAAAATGAGAAAGTTAGTATCTGCAATACAGAGCTT 
GTTCCTGTTCAGTGACTGACCCTCTGTATTCTGTATAGACACCAGGCCGATACACAGTGGAGTTCCCAGGCCTTGTTTGC 
AGGAAGCCGACTGTAAAGACAGCCCCAGCTCAAGGCTATTAGGTTGAATATTTGCTTTCATGAGTAAATGTGGATCTTTG 
GGGAATGGCTTCAAAATAAGTCACGAACACAAATTCTTTGTAAATTATGTAAATTCCTGTTTATATAAATTGGCAACAAC 
TTATACCGTCTGACAGTTCAAAATCTCTTTCAGCTGCGCTCTTCCCACCGAGCCGAGCTTACTGTGAGTGTGGAGATGTT 
ATCCCACCATGTAAAGTCGCCTGCGCAGGGGAGGGCTGCCCATCTCCCCAACCCAGTCACAGAGAGATAGGAAACGGCAT 
TTGAGTGGGTGTCCAGGGCCCCGTAGAGAGACATTTAAGATGGTGTATGACAGAGCATTGGCCTTGACCAAATGTTAAAT 
CCTCTGTGTGTATTTCATAAGTTATTACAGGTATAAAAGTGATGACCTATCATGAGGAAATGAAAGTGGCTGATTTGCTG 
GTAGGATTTTGTACAGTTTAGAGAAGCGATTATTTATTGTGAAACTGTTCTCCACTCCAACTCCTTTATGTGGATCTGTT 
CAAAGTAGTCACTGTATATACGTATAGAGAGGTAGATAGGTAGGTAGATTTTAAATTGCATTCTGAATACAAACTCATAC 
TCCTTAGAGCTTGAATTACATTTTTAAAATGCATATGTGCTGTTTGGCACCGTGGCAAGATGGTATCAGAGAGAAACCCA 
TCAATTGCTCAAATACTCAGAAAGTACTGTCAAAAGCCTAATAAAA 
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Fig.3. Nucleotide sequence and predicted amino acid sequences of the human prepro-endothelin 3. The amino acid and nucleotide sequences of 
mature ET-3 are boxed. The repeated sequence of the 8 amino acid residues and the cysteine-rich, endothelin-like sequence are underlined with 
a single line with an arrowhead and a doubleline, respectively. Intron insertion sites are indicated by arrowheads. The cleavage site of the signal 
sequences is indicated by an arrow. 
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18th in this cloned cDNA, because the consensus se- 
quence of (T or C) > 11 N(C or T)AG is located adja- 
cent to this GA sequence in the cloned human genomic 
ET-3 DNA (unpublished results). The splicing donor 
site, the 3 ‘-terminus of this exon, is GA of the 5th 
amino acid, Glu after the C-terminal amino acid Trp of 
ET-3(3). This is based on the fact that the ET-3 
genomic DNA has a consensus equence of a 5 ’ -intron 
junction, GTAAGT, which was also confirmed by us, 
and the intron was not found in this cDNA. 
While this manuscript was in preparation, cDNA 
cloning of human ET-3 from cDNA library of the 
hypothalamus was presented by K.D. Bloch et al. [J. 
Biol. Chem. (1989) 264, 18156-181611. However, the 
precursor was reported to consist of 238 residues 
whereas the one we derived from placenta has 224 
residues. Also, we found a 220 bp insertion in the 
3 ’ -noncoding region of ET-3 cDNA from the placenta. 
It is of particular interest that endothelin like se- 
quence, CysXCysXXXXXXXCysXXXCys, such a 
cysteine-rich sequence with cysteine residues at the 1, 3, 
11 and 15 positions was found to be conserved in the 
prepro-ET-3. This amino acid sequence has been found 
in prepro-ET-l at 35 or 36 amino acids downstream 
from the C-terminal of human and porcine ET-l(1.2). 
However, the meaning of this conserved sequence in 
both precursors of ET-l and ET-3 remains a question. 
REFERENCES 
111 
121 
[31 
3.3. Expression of ET-3 in COS-7 cells 
When the ET-3 expression plasmid, pTS 6009, was 
introduced into the COS-7 cells, immunoreactive ET-3 
was detected in the culture medium. The ET-3 content 
produced by COS-7 cells was 30 + 2 pg/ml culture 
medium at 72 h after DNA transfection. The COS-7 
cells themselves produced immunoreactive ET-l(ET-2) 
as described before [17]; the production of ET-3 may 
be inhibited in the processing from the precursor. The 
production of ET-3 by the COS-7 cells was not so high; 
however, we were able to confirm that the transcrip- 
tion, translation of this cloned ET-3 cDNA and the 
secretion of the mature form of ET-3 had proceeded. 
[41 
151 
[61 
171 
[81 
[91 
HOI 
1111 
Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., 
Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K. and Masaki, 
T. (1988) Nature 332, 411-415. 
Itoh, Y., Yanagisawa, M., Ohkubo, S., Kimura, C., Kosaka, 
T., Inoue, M., Mitsui, Y., Onda, H., Fujino, M. and Masaki, 
T. (1988) FEBS Lett. 231, 440-444. 
Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., Miyauchi, 
T., Goto, K. and Masaki, T. (1989) Proc. Natl. Acad. Sci. USA 
86, 2863-2867. 
Yanagisawa, M. and Masaki, T. (1989) Trends Pharmacol. Sci. 
10, 374-378. 
Matsumoto, H., Suzuki, N., Onda, H. and Fujino, M. (1990) 
Biochem. Biophys. Res. Commun, in press. 
Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982) Molecular 
Cloning: A Laboratory Manual, Cold Spring Harbor 
Laboratory, Cold Spring Harbor, NY. 
Suzuki, N., Matsumoto, H., Kitada, C., Masaki, T. and 
Fujino, M. (1989) J. Immunol. Methods 118, 245-250. 
Benton, W.D. and Davis, R.W. (1977) Science 196, 180-182. 
Yanisch-Perron, C., Vieira, J. and Messing, J. (1985) Gene 33, 
103-l 19. 
Though endothelin was first recognized as a 
vasoconstrictor peptide, many other biological func- 
tions have since been found; for example, it can in- 
crease Ca2+ in the cells, acts as a growth factor [18], 
and can inhibit renin release [20]. 
1121 
I131 
1141 
1151 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. 
Acad. Sci. USA. 74, 5463-5467. 
Connell, C., Fung, S., Heiner, C., Bridgham, J., Chakerian, 
V., Herton, E., Jones, B., Menchen, S., Mordan, W., Raff, 
M., Recknor, M., Smith, L., Springer, J., Woo, S. and 
Hunkapiller, M. (1987) Bio/Techniques 5, 342-347. 
Templeton, D. and Eckenhart, W. (1984) Mol. Cell. Biol. 4, 
817. 
The biological relationships among ET-l, ET-2 and 
ET-3 should soon be elucidated, and the significance of 
the expression of ET-l and ET-3 in the placenta should 
be revealed. The abundance of ET-3 in the brain should 
serve as a key to understanding the functions of the 
brain. Our presentation of direct evidence of ET-3 gene 
expression should contribute to further understanding 
of endothelins and how they function. 
1161 
1171 
I181 
1191 
Graham, N. and Van der Eb, A. (1977) Virology 52, 456-467. 
Suzuki, N., Matsumoto, H., Kitada, C., Kimura, S. and 
Fujino, M. (1990) J. Biochem. (Tokyo) in press. 
Miyauchi, T., Yanagisawa, M., Tomizawa, T., Sugishita, Y., 
Suzuki, N., Fujino, M., Ajisaka, R., Goto, K. and Masaki, T. 
(1989) Lancet ii, 53-54. 
Von Heijne, G. (1986) Nucleic Acids Res. 14, 4683-4690. 
Kosaka, T., Suzuki, N., Matsumoto, H., Itoh, Y., Yasuhara, 
T., Onda, H. and Fujino, M. (1989) FEBS Lett. 249, 42-46. 
Komuro, I., Kurihara, H., Sugiyarna, T., Takaku, F. and 
Yazaki, Y. (1988) FBBS Lett. 238, 249-252. 
Rakugi, H., Nakamura, M., Saito, H., Higaki, J. and Ogihara, 
T. (1988) Biochem. Biophys. Res. Commun. 155, 1244-1247. 
330 
